Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
521. |
ECCT/21/11/01 | VAT 00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Walter Godfrey Jaoko Site(s) in Kenya 1. Kenya Medical Research Institute (Kisumu county) 2. KEMRI/Walter Reed Project Research Center (Kericho county) 3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county) 4. KEMRI CMR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 7. Moi University Clinical Research Centre (Uasin Gishu county) 8. Aga Khan University Hospital (Nairobi City county) 9. KEMRI CCR-Butere County Hospital Site (Kakamega county) 10. Ganjoni Clinic (Mombasa county) |
View |
522. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
View |
523. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
View |
524. |
ECCT/17/09/01 | HPTN 084 HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
Principal Investigator(s) 1. Samuel Gurrion Ouma Site(s) in Kenya KISUMU CRS |
View |
525. |
ECCT/25/07/05 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Elgeyo/Marakwet county) 3. KEMRI-WRP (Kericho county) 4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
View |